RxSight, Inc. Common Stock (RXST) — Analysis Summary
RxSight, Inc. Common Stock (RXST) has a market cap of $274.93M with year-over-year revenue growth of -3.9%. Net margin stands at -29.0%. The stock trades at a P/E ratio of -5.9.
Key Takeaways
- Revenue changed -3.9% year-over-year
- Net margin of -29.0%
- P/E ratio of -5.9
Compared to other companies in the OPHTHALMIC GOODS sector, RXST posted revenue growth of -3.9% and trades at a P/E of -5.9.
RxSight, Inc. Common Stock (RXST)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -3936.6x — earnings do not cover interest payments
Operating margin at -45.5% — material operating losses
Net margin at -38.8% — significant losses
The latest filing shows negative free cash flow.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Sector
OPHTHALMIC GOODS
Employees
461
Headquarters
ALISO VIEJO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.